Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
Hai V NguyenShweta MitalDavid S KnopmanG Caleb AlexanderPublished in: Neurology (2024)
ε4 genotype is cost-effective vs SoC alone for patients with MCI or mild dementia due to AD. Lecanemab would be cost-effective in some settings if priced below $5,100 per year.